Home › Acute Myeloid Leukemia › Rhode Island
Acute Myeloid Leukemia clinical trials in Rhode Island
12 studies for Acute Myeloid Leukemia are looking for participants at sites in Rhode Island.
Cities in Rhode Island
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Rhode Island Hospital, Providence
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Rhode Island Hospital, Providence
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Nov 9, 2026 · NCT05554406Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Rhode Island Hospital, Providence
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Nov 6, 2026 · NCT07437950Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Kent Hospital, Warwick
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Rhode Island Hospital, Providence
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT05564390Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Rhode Island Hospital, Providence
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Oct 28, 2026 · NCT05554393Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Rhode Island Hospital, Providence
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06672146Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Clinical Trial Site, Providence
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Oct 21, 2026 · NCT07211958A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Rhode Island Hospital, Providence
RecruitingPhase 3
6 Months – 21 Years · All sexes · Updated Sep 17, 2026 · NCT04293562The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Rhode Island Hospital, Providence
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- University of Rhode Island, Providence
RecruitingPhase 2/3
Ages 18 to 80 · All sexes · Updated Aug 5, 2026 · NCT06788756Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
- Lifespan Health System Rhode Island Hospital, Providence
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 10, 2026 · NCT05442216From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.